DK3312177T3 - Tricyklisk derivatforbindelse, fremgangsmåde til at fremstille samme og farmaceutisk sammensætning omfattende samme - Google Patents
Tricyklisk derivatforbindelse, fremgangsmåde til at fremstille samme og farmaceutisk sammensætning omfattende samme Download PDFInfo
- Publication number
- DK3312177T3 DK3312177T3 DK16807741.0T DK16807741T DK3312177T3 DK 3312177 T3 DK3312177 T3 DK 3312177T3 DK 16807741 T DK16807741 T DK 16807741T DK 3312177 T3 DK3312177 T3 DK 3312177T3
- Authority
- DK
- Denmark
- Prior art keywords
- same
- preparing
- pharmaceutical composition
- composition including
- derivative compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150081021 | 2015-06-09 | ||
PCT/KR2016/005911 WO2016200101A2 (ko) | 2015-06-09 | 2016-06-03 | 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3312177T3 true DK3312177T3 (da) | 2021-07-05 |
Family
ID=57503424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16807741.0T DK3312177T3 (da) | 2015-06-09 | 2016-06-03 | Tricyklisk derivatforbindelse, fremgangsmåde til at fremstille samme og farmaceutisk sammensætning omfattende samme |
Country Status (21)
Country | Link |
---|---|
US (1) | US10464919B2 (da) |
EP (1) | EP3312177B1 (da) |
JP (2) | JP2018521033A (da) |
KR (1) | KR101837047B1 (da) |
CN (1) | CN107849040B (da) |
AU (1) | AU2016276806B9 (da) |
BR (1) | BR112017026392B1 (da) |
CA (1) | CA2990277C (da) |
CL (1) | CL2017003138A1 (da) |
DK (1) | DK3312177T3 (da) |
ES (1) | ES2870203T3 (da) |
MX (1) | MX2017016013A (da) |
MY (1) | MY194590A (da) |
NZ (1) | NZ738187A (da) |
PH (1) | PH12017502228A1 (da) |
PL (1) | PL3312177T3 (da) |
PT (1) | PT3312177T (da) |
RU (1) | RU2715413C2 (da) |
SA (1) | SA517390509B1 (da) |
WO (1) | WO2016200101A2 (da) |
ZA (1) | ZA201708663B (da) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3312177T (pt) * | 2015-06-09 | 2021-05-17 | Onconic Therapeutics Inc | Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo |
US10435403B2 (en) | 2015-06-09 | 2019-10-08 | Bayer Pharma Aktiengesellschaft | Positive allosteric modulators of muscarinic M2 receptor |
KR101775356B1 (ko) | 2015-07-06 | 2017-09-06 | 재단법인 아산사회복지재단 | Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법 |
US10519154B2 (en) | 2016-07-11 | 2019-12-31 | Bayer Pharma Aktiengesellschaft | 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof |
JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
CN108727377A (zh) * | 2017-04-14 | 2018-11-02 | 四川大学 | 3-氰基吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途 |
CN111566105A (zh) | 2018-01-08 | 2020-08-21 | 豪夫迈·罗氏有限公司 | 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物 |
WO2020155141A1 (zh) * | 2019-02-02 | 2020-08-06 | 中国科学院上海有机化学研究所 | 治疗神经退行性疾病或rna结合蛋白发生异常导致的疾病的药物组合物及其应用 |
JP2022527590A (ja) * | 2019-04-09 | 2022-06-02 | エフ.ホフマン-ラ ロシュ アーゲー | モノアシルグリセロールリパーゼ(magl)の阻害剤としての複素環式化合物 |
MX2022000711A (es) * | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
CA3146528A1 (en) * | 2019-07-29 | 2021-02-04 | Jeil Pharmaceutical Co.,Ltd | Method for treating stroke by using tricyclic derivative |
US20220324899A1 (en) * | 2019-08-14 | 2022-10-13 | Metro International Biotech, Llc | Compounds and compositions for differential modulation of nicotinamide adenine dinucleotide |
US11795158B2 (en) * | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
GB202012969D0 (en) * | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
JP2024514223A (ja) * | 2021-04-19 | 2024-03-28 | シンセラ, インコーポレイテッド | Parp1阻害薬及びその使用 |
WO2022222921A1 (zh) * | 2021-04-22 | 2022-10-27 | 微境生物医药科技(上海)有限公司 | 含哌嗪结构的parp抑制剂、其制备方法及医药用途 |
TW202304911A (zh) * | 2021-04-23 | 2023-02-01 | 大陸商南京明德新藥研發有限公司 | 吡啶醯胺類化合物 |
WO2022222966A1 (zh) * | 2021-04-23 | 2022-10-27 | 成都百裕制药股份有限公司 | 一种选择性parp1抑制剂及其应用 |
EP4342898A1 (en) | 2021-05-18 | 2024-03-27 | Onconic Therapeutics Inc. | Crystalline form of tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same |
IL308325A (en) | 2021-05-18 | 2024-01-01 | Onconic Therapeutics Inc | A PARP-resistant cancer therapeutic agent |
TWI820847B (zh) * | 2021-08-05 | 2023-11-01 | 大陸商上海樞境生物科技有限公司 | 含三并環類衍生物調節劑、其製備方法和應用 |
WO2023025307A1 (en) * | 2021-08-27 | 2023-03-02 | Impact Therapeutics (Shanghai) , Inc | Substituted tricyclic compounds as parp inhibitors and use thereof |
WO2023036285A1 (zh) * | 2021-09-09 | 2023-03-16 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药(杭州)有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
TW202322807A (zh) | 2021-10-01 | 2023-06-16 | 美商辛瑟拉股份有限公司 | 吖丁啶及吡咯啶parp1抑制劑及其用途 |
WO2023061406A1 (zh) * | 2021-10-12 | 2023-04-20 | 微境生物医药科技(上海)有限公司 | 含三并环结构的parp抑制剂、及其制备方法和医药用途 |
WO2023122140A1 (en) * | 2021-12-22 | 2023-06-29 | Synnovation Therapeutics, Inc. | Parp1 inhibitors |
WO2023134647A1 (zh) * | 2022-01-13 | 2023-07-20 | 优领医药科技(香港)有限公司 | 含哌嗪并环类衍生物、其药学上可接受的盐及其制备方法和应用 |
US11939329B2 (en) | 2022-01-21 | 2024-03-26 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
WO2023169226A1 (en) * | 2022-03-11 | 2023-09-14 | Impact Therapeutics (Shanghai), Inc | Substituted tricyclic compounds as parp inhibitors and the use thereof |
WO2023212219A1 (en) | 2022-04-28 | 2023-11-02 | Xinthera, Inc. | Tricyclic parp1 inhibitors and uses thereof |
WO2023217045A1 (zh) * | 2022-05-07 | 2023-11-16 | 南京明德新药研发有限公司 | 选择性抑制parp1的氟代喹喔啉酮衍生物 |
CN115232129B (zh) * | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
WO2024041608A1 (zh) * | 2022-08-24 | 2024-02-29 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂的晶体形式及其用途 |
WO2024041605A1 (zh) * | 2022-08-24 | 2024-02-29 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5391554A (en) * | 1992-09-09 | 1995-02-21 | Warner-Lambert Company | Dihydro- and tetrahydronaphthyridines |
AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
DE102004028973A1 (de) | 2004-06-16 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
CA2661842C (en) * | 2006-09-01 | 2017-08-22 | Cylene Pharmaceuticals, Inc. | Tricyclic heteroaryl compounds and their use as serine-threonine protein kinases and parp modulators |
US8404713B2 (en) * | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
KR101179753B1 (ko) | 2007-11-06 | 2012-09-04 | 제일약품주식회사 | 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물 |
RU2470934C1 (ru) * | 2008-11-11 | 2012-12-27 | Дзе Ил Фармасьютикал Ко., Лтд. | Новое трициклическое производное или его фармацевтически приемлемые соли, способ их получения и содержащая их фармацевтическая композиция |
KR101827444B1 (ko) * | 2012-02-01 | 2018-02-08 | 제일약품주식회사 | 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법 |
PT3312177T (pt) * | 2015-06-09 | 2021-05-17 | Onconic Therapeutics Inc | Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo |
KR101775356B1 (ko) * | 2015-07-06 | 2017-09-06 | 재단법인 아산사회복지재단 | Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법 |
-
2016
- 2016-06-03 PT PT168077410T patent/PT3312177T/pt unknown
- 2016-06-03 EP EP16807741.0A patent/EP3312177B1/en active Active
- 2016-06-03 WO PCT/KR2016/005911 patent/WO2016200101A2/ko active Application Filing
- 2016-06-03 CN CN201680040992.8A patent/CN107849040B/zh active Active
- 2016-06-03 MY MYPI2017704653A patent/MY194590A/en unknown
- 2016-06-03 JP JP2017564557A patent/JP2018521033A/ja not_active Ceased
- 2016-06-03 CA CA2990277A patent/CA2990277C/en active Active
- 2016-06-03 MX MX2017016013A patent/MX2017016013A/es active IP Right Grant
- 2016-06-03 ES ES16807741T patent/ES2870203T3/es active Active
- 2016-06-03 BR BR112017026392-0A patent/BR112017026392B1/pt active IP Right Grant
- 2016-06-03 US US15/579,692 patent/US10464919B2/en active Active
- 2016-06-03 DK DK16807741.0T patent/DK3312177T3/da active
- 2016-06-03 PL PL16807741T patent/PL3312177T3/pl unknown
- 2016-06-03 AU AU2016276806A patent/AU2016276806B9/en active Active
- 2016-06-03 RU RU2017146130A patent/RU2715413C2/ru active
- 2016-06-03 KR KR1020160069199A patent/KR101837047B1/ko active IP Right Grant
- 2016-06-03 NZ NZ738187A patent/NZ738187A/en unknown
-
2017
- 2017-12-07 CL CL2017003138A patent/CL2017003138A1/es unknown
- 2017-12-07 PH PH12017502228A patent/PH12017502228A1/en unknown
- 2017-12-07 SA SA517390509A patent/SA517390509B1/ar unknown
- 2017-12-19 ZA ZA2017/08663A patent/ZA201708663B/en unknown
-
2019
- 2019-05-09 JP JP2019088851A patent/JP6806969B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3312177T3 (da) | Tricyklisk derivatforbindelse, fremgangsmåde til at fremstille samme og farmaceutisk sammensætning omfattende samme | |
HK1243999A1 (zh) | 新型3-吲哚取代的衍生物、藥物組合物及使用方法 | |
DK3676297T3 (da) | Forbindelser, sammensætninger og fremgangsmåder | |
DK3643709T3 (da) | Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf | |
DK3486242T3 (da) | Oxopicolinamidderivat, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf | |
DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
DK3204386T3 (da) | Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed | |
HK1232229A1 (zh) | '- '-硫代核苷的新型化合物及其製備方法、藥物組合物和應用 | |
DK3408326T3 (da) | Elastomerartikler, sammensætninger og fremgangsmåder til fremstilling deraf | |
DK3383436T3 (da) | Forbedret fremgangsmåde til fremstilling af indocyaningrønt | |
PT3580208T (pt) | Derivados de 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ol e compostos relacionados como inibidores de prs para tratamento de, por exemplo, cancro | |
DK3255042T3 (da) | Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme | |
DK3750893T3 (da) | Dioxazolinforbindelse, fremgangsmåde til fremstilling deraf og anvendelser deraf | |
DK3404024T3 (da) | Quinazolinonderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning og anvendelser | |
DK3265443T3 (da) | Pyrrolidincarboxamidderivater og fremgangsmåde til fremstilling og anvendelse af samme | |
DK3315181T3 (da) | Sammensat emne og fremgangsmåde til at fremstille samme | |
HRP20200104T8 (hr) | Novi heterociklični spoj, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto | |
DK3383397T3 (da) | Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin | |
DK3328368T3 (da) | Forbindelser og farmaceutisk sammensætning associeret med ubiquitinering-proteasomsystem | |
DK3389633T3 (da) | Farmaceutiske sammensætninger, der omfatter phenylaminopyrimidinderivat | |
DK3091005T3 (da) | 1,2-naphthoquinonderivat og fremgangsmåde til fremstilling deraf | |
DK3360863T3 (da) | Etomidatderivat og mellemprodukt, fremgangsmåde til fremstilling og anvendelse deraf | |
DK3288933T3 (da) | Oxindolforbindelser og farmaceutiske sammensætninger deraf | |
DK3207023T3 (da) | Fremgangsmåde til fremstilling af 1-(3,5-dichlorphenyl)-2,2,2-trifluorethanon og derivater deraf | |
PL3176164T3 (pl) | Izomer optyczny pochodnej 1-tlenku 1,4-benzotiazepiny oraz farmaceutyczna kompozycja wytworzona z jego użyciem |